CS
CADX

Credit Suisse’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

Credit Suisse’s Portfolio CADX Stock Details CADX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-92,086
Closed -$833K – 4990
2013
Q4 		$833K Buy
92,086
+16,383
+22% +$118K ﹤0.01% 3420
2013
Q3 		$477K Buy
75,703
+23,330
+45% +$148K ﹤0.01% 3523
2013
Q2 		$357K Buy
+52,373
New +$365K ﹤0.01% 3520

Other funds holding CADX

OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Credit Suisse's CADX Position: Q1 2014 in Review

Credit Suisse sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q1 2014, closing a stake of 92,086 shares — an estimated $833K sold.

Credit Suisse first reported a position in CADX in Q2 2013 and held it in 3 quarters. The position peaked at $833K in Q4 2013. 3 funds tracked by Wall St. Rank hold CADX as of Q1 2014.

  • Credit Suisse reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q1 2014 after selling out during the quarter.
  • Credit Suisse sold 92,086 CADENCE PHARMACEUTICALS, INC COM STK shares in Q1 2014, an estimated $833K.
  • Credit Suisse first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q2 2013 and held it in 3 quarters.
  • Credit Suisse's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $833K in Q4 2013.
  • 3 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q1 2014.

Based on Credit Suisse's 13F filing for Q1 2014, filed 15 May 2014.